National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report.
Allogeneic hematopoietic cell transplantation
Chronic graft-versus-host disease
Consensus
Preemptive therapy
Risk assignment biomarkers
Journal
Transplantation and cellular therapy
ISSN: 2666-6367
Titre abrégé: Transplant Cell Ther
Pays: United States
ID NLM: 101774629
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
26
03
2021
accepted:
30
03
2021
pubmed:
10
4
2021
medline:
3
8
2021
entrez:
9
4
2021
Statut:
ppublish
Résumé
Chronic graft-versus-host disease (GVHD) commonly occurs after allogeneic hematopoietic cell transplantation (HCT) despite standard prophylactic immune suppression. Intensified universal prophylaxis approaches are effective but risk possible overtreatment and may interfere with the graft-versus-malignancy immune response. Here we summarize conceptual and practical considerations regarding preemptive therapy of chronic GVHD, namely interventions applied after HCT based on evidence that the risk of developing chronic GVHD is higher than previously appreciated. This risk may be anticipated by clinical factors or risk assignment biomarkers or may be indicated by early signs and symptoms of chronic GVHD that do not fully meet National Institutes of Health diagnostic criteria. However, truly preemptive, individualized, and targeted chronic GVHD therapies currently do not exist. In this report, we (1) review current knowledge regarding clinical risk factors for chronic GVHD, (2) review what is known about chronic GVHD risk assignment biomarkers, (3) examine how chronic GVHD pathogenesis intersects with available targeted therapeutic agents, and (4) summarize considerations for preemptive therapy for chronic GVHD, emphasizing trial development, including trial design and statistical considerations. We conclude that robust risk assignment models that accurately predict chronic GVHD after HCT and early-phase preemptive therapy trials represent the most urgent priorities for advancing this novel area of research.
Identifiants
pubmed: 33836313
pii: S2666-6367(21)00820-4
doi: 10.1016/j.jtct.2021.03.029
pmc: PMC8934187
mid: NIHMS1755099
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
632-641Subventions
Organisme : CSRD VA
ID : IK2 CX001785
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA BC011743
Pays : United States
Informations de copyright
Copyright © 2021. Published by Elsevier Inc.
Références
Br J Ophthalmol. 2017 Mar;101(3):322-326
pubmed: 27267447
Blood. 2017 Nov 23;130(21):2243-2250
pubmed: 28924018
Oncologist. 2020 Feb;25(2):e328-e334
pubmed: 32043777
Blood Adv. 2020 Dec 22;4(24):6098-6105
pubmed: 33351103
Blood. 2013 Jun 20;121(25):5098-103
pubmed: 23547053
Biol Blood Marrow Transplant. 2008 Feb;14(2):208-19
pubmed: 18215781
Transplant Cell Ther. 2021 Aug;27(8):632-641
pubmed: 33836313
Blood. 2017 Jan 12;129(2):162-170
pubmed: 27827824
Blood. 2012 Jan 12;119(2):619-28
pubmed: 22077059
Biol Blood Marrow Transplant. 2018 Mar;24(3):521-528
pubmed: 29155316
JCI Insight. 2017 Jun 15;2(12):
pubmed: 28614794
Blood. 2017 May 4;129(18):2570-2580
pubmed: 28254742
Bone Marrow Transplant. 2010 Nov;45(11):1653-7
pubmed: 20190833
Biol Blood Marrow Transplant. 2011 Dec;17(12):1804-13
pubmed: 21669298
Blood. 2010 Aug 5;116(5):819-28
pubmed: 20435882
Blood Adv. 2018 Aug 14;2(15):1882-1888
pubmed: 30087106
Blood Adv. 2019 Apr 9;3(7):1003-1010
pubmed: 30940635
Biol Blood Marrow Transplant. 2007 Apr;13(4):386-97
pubmed: 17382246
Bone Marrow Transplant. 2017 Apr;52(4):625-626
pubmed: 27991888
Blood. 2011 Feb 17;117(7):2275-83
pubmed: 21097674
Blood. 2012 Sep 20;120(12):2529-36
pubmed: 22896003
Blood. 2016 Jul 7;128(1):130-7
pubmed: 27073224
Am J Respir Crit Care Med. 2015 Jun 1;191(11):1242-9
pubmed: 25835160
Biol Blood Marrow Transplant. 2011 Jan;17(1):1-17
pubmed: 20685255
Bone Marrow Transplant. 2016 Jun;51(6):890
pubmed: 27245090
J Clin Invest. 2014 Nov;124(11):4867-76
pubmed: 25271622
Blood. 2014 Jun 19;123(25):3988-98
pubmed: 24820310
Blood. 2021 May 6;137(18):2544-2557
pubmed: 33534893
Haematologica. 2017 Nov;102(11):1936-1946
pubmed: 28935847
Biol Blood Marrow Transplant. 2017 Aug;23(8):1257-1263
pubmed: 28478120
Bone Marrow Transplant. 2015 Feb;50(2):253-8
pubmed: 25365068
Blood. 2011 Dec 15;118(25):6702-8
pubmed: 21979939
Blood. 2020 May 14;135(20):1739-1749
pubmed: 32160294
Blood. 2008 Mar 15;111(6):3276-85
pubmed: 17925486
Ann Am Thorac Soc. 2016 Nov;13(11):1932-1939
pubmed: 27513368
N Engl J Med. 2017 Dec 28;377(26):2565-2579
pubmed: 29281578
J Clin Invest. 2015 Jul 1;125(7):2677-89
pubmed: 26053664
Sci Transl Med. 2010 Jan 6;2(13):13ra2
pubmed: 20371463
N Engl J Med. 2017 Jul 6;377(1):62-70
pubmed: 28679092
Blood. 2019 Dec 5;134(23):2092-2106
pubmed: 31578204
J Clin Oncol. 2016 Aug 1;34(22):2583-90
pubmed: 27217465
Blood. 2019 Jan 3;133(1):94-99
pubmed: 30279226
Biol Blood Marrow Transplant. 2015 May;21(5):780-92
pubmed: 25644957
Blood. 2015 Sep 24;126(13):1609-20
pubmed: 26206951
Biol Blood Marrow Transplant. 2020 Feb;26(2):392-400
pubmed: 31682980
JAMA. 2017 Aug 8;318(6):557-566
pubmed: 28787506
Blood. 2017 Jun 8;129(23):3121-3125
pubmed: 28416503
Blood. 2014 Jan 30;123(5):786-93
pubmed: 24363401
Blood. 2011 Mar 17;117(11):3214-9
pubmed: 21263156
Blood. 2009 Dec 17;114(26):5375-84
pubmed: 19843883
Blood Adv. 2019 Dec 10;3(23):4034-4042
pubmed: 31816061
Biol Blood Marrow Transplant. 2016 Oct;22(10):1781-1791
pubmed: 27343720
Blood. 2014 Mar 27;123(13):2108-15
pubmed: 24532806
Blood Adv. 2019 May 14;3(9):1553-1562
pubmed: 31088809
Am J Transplant. 2019 Jun;19(6):1820-1830
pubmed: 30748099
J Clin Invest. 2010 May;120(5):1479-93
pubmed: 20389017
Bone Marrow Transplant. 2005 Aug;36(4):337-41
pubmed: 15968296
J Immunol. 2010 Jan 15;184(2):764-74
pubmed: 19995899
Blood. 2015 Jul 2;126(1):113-20
pubmed: 25987657
Front Immunol. 2020 Apr 09;11:636
pubmed: 32373119
Sci Transl Med. 2013 Apr 3;5(179):179ra43
pubmed: 23552371
Blood. 2016 Jun 16;127(24):3082-91
pubmed: 27020088
Blood. 2014 Jun 12;123(24):3832-42
pubmed: 24711661
Blood. 2018 Jun 21;131(25):2846-2855
pubmed: 29545329
Blood. 2020 Apr 9;135(15):1287-1298
pubmed: 32047896
Biol Blood Marrow Transplant. 2015 Feb;21(2):250-8
pubmed: 25460358
Bone Marrow Transplant. 2018 Jul;53(7):832-837
pubmed: 29367715
Blood. 2017 Jan 5;129(1):13-21
pubmed: 27821504
Front Immunol. 2020 Oct 16;11:571884
pubmed: 33193355
N Engl J Med. 2013 Aug 8;369(6):529-39
pubmed: 23924003
Blood. 2015 Jun 25;125(26):4085-94
pubmed: 25852057
Blood. 2016 Apr 28;127(17):2144-54
pubmed: 26983850
JCI Insight. 2018 Oct 4;3(19):
pubmed: 30282825
Blood. 2020 May 7;135(19):1630-1638
pubmed: 32202630
N Engl J Med. 2011 Dec 1;365(22):2055-66
pubmed: 22129252
Blood. 2011 Oct 13;118(15):4250-7
pubmed: 21791415
Am J Transplant. 2018 Apr;18(4):810-820
pubmed: 28941323
Blood. 2020 Jan 9;135(2):97-107
pubmed: 31738834
Clin Cancer Res. 2007 Oct 15;13(20):6107-14
pubmed: 17947475
Curr Opin Pulm Med. 2012 May;18(3):264-70
pubmed: 22388587
Blood. 2009 Apr 16;113(16):3865-74
pubmed: 19168788
Biol Blood Marrow Transplant. 2016 Jan;22(1):134-40
pubmed: 26365153
JCI Insight. 2017 Feb 9;2(3):e89798
pubmed: 28194439
Blood. 2014 Sep 4;124(10):1677-88
pubmed: 25009225
Blood. 2012 Jun 21;119(25):6145-54
pubmed: 22563089
Med Oncol. 2018 Apr 25;35(6):79
pubmed: 29696461
Blood. 2007 Feb 15;109(4):1756-64
pubmed: 17032915
Blood. 2008 Aug 15;112(4):1539-42
pubmed: 18502834
J Clin Invest. 2014 Oct;124(10):4266-80
pubmed: 25157821